A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
The purpose of this study is to see how safe and effective an investigational drug, RTH258, is in people who have age-related macular degeneration (AMD). This is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving. The form of advanced AMD investigated in this clinical study is commonly referred to as wet AMD.
Study Doctors: Christina Weng, M.D., Ella Leung, M.D., and Tahira Scholle, M.D.
For study details, please see Efficacy and Safety of RTH258 Versus Aflibercept.